Literature DB >> 8824555

Different effects of interferons, interleukin-1beta and tumor necrosis factor-alpha in normal (OSE) and malignant human ovarian epithelial cells.

C Marth1, A G Zeimet, M Herold, C Brumm, G Windbichler, E Müller-Holzner, F Offner, H Feichtinger, H Zwierzina, G Daxenbichler.   

Abstract

Ovarian cancer arises mostly from the ovarian surface epithelium. The aim of our study was to compare the effects of cytokines in ovarian surface epithelial (OSE) cells and in ovarian carcinoma cells. Proliferation and expression of surface antigens (CA-125 and classes I and II antigens of the major histocompatibility complex [MHC]) were measured in OSE cells obtained from 7 different patients and 7 ovarian carcinoma cell lines. Proliferation of OSE cells remained unaffected by interferon (IFN)-alpha or IFN-gamma, whereas interleukin-1 (IL-1) and tumor necrosis factor (TNF) increased cell growth. Proliferation of ovarian carcinoma cells was reduced by both types of IFN as well as TNF but was not affected by IL-1. Expression of the tumor marker CA-125 was increased by IFN-gamma in ovarian carcinoma cells but not by any other treatment. None of the cytokines affected CA-125 surface expression in OSE cells. Expression of MHC-I was augmented in OSE and in carcinoma cells by both IFNs but not by the other cytokines. Both types of cell were negative for MHC-II, but IFN-gamma induced its expression in both OSE and carcinoma cells. Significant concentrations of the cytokines evaluated here have been measured in blood and follicular fluid by several authors. The different actions of these cytokines in OSE and carcinoma cells could therefore be important in understanding the role of such molecules in the regulation of physiological and pathological processes in the ovary, such as ovulation or malignant proliferation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8824555     DOI: 10.1002/(SICI)1097-0215(19960917)67:6<826::AID-IJC12>3.0.CO;2-#

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  12 in total

1.  Expression of interleukin-1 (IL-1) ligands system in the most common endometriosis-associated ovarian cancer subtypes.

Authors:  Mamadou Keita; Paul Bessette; Manuella Pelmus; Youssef Ainmelk; Aziz Aris
Journal:  J Ovarian Res       Date:  2010-01-28       Impact factor: 4.234

2.  Interleukin-1 Gene Cluster Polymorphisms and its Haplotypes may Predict the Risk to Develop Cervical Cancer in Tunisia.

Authors:  Sabrina Zidi; Ikram Sghaier; Ferjeni Zouidi; Amira Benahmed; Mouna Stayoussef; Radhia Kochkar; Ezzedine Gazouani; Amel Mezlini; Besma Yacoubi-Loueslati
Journal:  Pathol Oncol Res       Date:  2015-04-30       Impact factor: 3.201

3.  Drug Transporter-Mediated Protection of Cancer Stem Cells From Ionophore Antibiotics.

Authors:  Maximilian Boesch; Alain G Zeimet; Holger Rumpold; Guenther Gastl; Sieghart Sopper; Dominik Wolf
Journal:  Stem Cells Transl Med       Date:  2015-07-01       Impact factor: 6.940

4.  Effects of interferon beta on transcobalamin II-receptor expression and antitumor activity of nitrosylcobalamin.

Authors:  Joseph A Bauer; Bei H Morrison; Ronald W Grane; Barbara S Jacobs; Sally Dabney; Ana M Gamero; Kevin A Carnevale; Daniel J Smith; Judith Drazba; Bellur Seetharam; Daniel J Lindner
Journal:  J Natl Cancer Inst       Date:  2002-07-03       Impact factor: 13.506

5.  Inflammatory cytokine tumor necrosis factor alpha confers precancerous phenotype in an organoid model of normal human ovarian surface epithelial cells.

Authors:  Joseph Kwong; Franky Leung Chan; Kwong-kwok Wong; Michael J Birrer; Kyra M Archibald; Frances R Balkwill; Ross S Berkowitz; Samuel C Mok
Journal:  Neoplasia       Date:  2009-06       Impact factor: 5.715

Review 6.  Immune response in ovarian cancer: how is the immune system involved in prognosis and therapy: potential for treatment utilization.

Authors:  Nikos G Gavalas; Alexandra Karadimou; Meletios A Dimopoulos; Aristotelis Bamias
Journal:  Clin Dev Immunol       Date:  2011-01-24

7.  Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial.

Authors:  G H Windbichler; H Hausmaninger; W Stummvoll; A H Graf; C Kainz; J Lahodny; U Denison; E Müller-Holzner; C Marth
Journal:  Br J Cancer       Date:  2000-03       Impact factor: 7.640

8.  Inflammation-associated gene expression is altered between normal human ovarian surface epithelial cells and cell lines derived from ovarian adenocarcinomas.

Authors:  O Gubbay; W Guo; M T Rae; D Niven; S P Langdon; S G Hillier
Journal:  Br J Cancer       Date:  2005-05-23       Impact factor: 7.640

9.  ST6Gal-I expression in ovarian cancer cells promotes an invasive phenotype by altering integrin glycosylation and function.

Authors:  Daniel R Christie; Faheem M Shaikh; John A Lucas; John A Lucas; Susan L Bellis
Journal:  J Ovarian Res       Date:  2008-10-01       Impact factor: 4.234

10.  The MOC31PE immunotoxin reduces cell migration and induces gene expression and cell death in ovarian cancer cells.

Authors:  Merete Thune Wiiger; Hemaseh Bideli; Oystein Fodstad; Kjersti Flatmark; Yvonne Andersson
Journal:  J Ovarian Res       Date:  2014-02-15       Impact factor: 4.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.